Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Dec 20:2021:2324400.
doi: 10.1155/2021/2324400. eCollection 2021.

Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review

Ji Wen  1 , Huifang Hu  1 , Menglin Chen  2 , Hang Yang  1 , Yi Zhao  1 , Yi Liu  1
Affiliations
Meta-Analysis

Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review

Ji Wen et al. J Immunol Res. .

Abstract

Purpose: To evaluate the effectiveness of Janus kinase (JAK) inhibitors for the treatment of patients with autoimmune disease and associated inflammatory ocular diseases.

Methods: We identified relevant literature by screening the MEDLINE, PubMed, and Cochrane databases for randomized controlled trials, cohort studies, case controls, and case reports.

Results: Seven studies, including 11 patients, were included in the final systematic analysis. Of the 11 patients, there were 5 cases of juvenile idiopathic arthritis- (JIA-) associated uveitis, 1 case of rheumatoid arthritis- (RA-) associated keratitis, 1 case of RA-associated scleritis, 1 case of psoriasis-associated conjunctivitis, 2 cases of noninfectious scleritis, and 1 case of uveitis with suspected autoimmune disease. None of these 11 patients responded adequately to conventional treatments, including biological agents; these were all refractory cases and switched to JAK inhibitor therapy. Irrespective of whether they were suffering from uveitis, scleritis, or other types of ocular inflammation, all 11 patients showed an improvement to JAK inhibitors without significant side effects. Different types of JAK inhibitors might be associated with different responses when used to treat ocular inflammation.

Conclusions: JAK inhibitors may represent an alternative treatment option for patients with autoimmune ocular inflammation.

PubMed Disclaimer

Conflict of interest statement

None of the authors have any conflicts of interest to declare.

Figures

Figure 1
Figure 1
The flow diagram of the reviewed literature.
See this image and copyright information in PMC

References

    1. Wakefield D., di Girolamo N., Thurau S., Wildner G., McCluskey P. Scleritis: immunopathogenesis and molecular basis for therapy. Progress in Retinal and Eye Research . 2013;35:44–62. doi: 10.1016/j.preteyeres.2013.02.004. - DOI - PubMed
    1. Horton S., Jones A. P., Guly C. M., et al. Adalimumab in juvenile idiopathic arthritis-associated uveitis: 5-year follow-up of the bristol participants of the SYCAMORE trial. American Journal of Ophthalmology . 2019;207:170–174. doi: 10.1016/j.ajo.2019.06.007. - DOI - PubMed
    1. Suhler E. B., Lim L. L., Beardsley R. M., et al. Rituximab therapy for refractory scleritis: results of a phase I/II dose- ranging, randomized, clinical trial. Ophthalmology . 2014;121(10):1885–1891. doi: 10.1016/j.ophtha.2014.04.044. - DOI - PubMed
    1. Dipasquale V., Atteritano M., Fresta J., Castagna I., Conti G. Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: a report of two cases. Journal of Clinical Pharmacy and Therapeutics . 2019;44(3):482–485. doi: 10.1111/jcpt.12821. - DOI - PubMed
    1. Ragam A., Kolomeyer A. M., Fang C., Xu Y., Chu D. S. Treatment of chronic, noninfectious, nonnecrotizing scleritis with tumor necrosis factor alpha inhibitors. Ocular Immunology and Inflammation . 2014;22(6):469–477. doi: 10.3109/09273948.2013.863944. - DOI - PubMed

MeSH terms

Substances